Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Hepatocellular 7Neoplasm Metastasis 5Colorectal Neoplasms 5Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumor 4Solid Tumor 3Small Cell Lung Carcinoma 3Lung Neoplasms 3Esophageal Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Rectal Neoplasms 2Melanoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumour 2Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Metastatic Solid Tumors 1

Interventions

Specimen Handling 53pembrolizumab 50Carboplatin 50Magnetic Resonance Spectroscopy 46Pemetrexed 40Cisplatin 35durvalumab 24Paclitaxel 24osimertinib 21Nivolumab 21Gemcitabine 19Radiosurgery 17Docetaxel 17atezolizumab 15Immunoglobulin G 15Radiotherapy 14Disulfides 14Biopsy 14Taxes 12130-nm albumin-bound paclitaxel 12Radiation 11Etoposide 11Educational Status 11Blood Specimen Collection 11Drug Therapy 10Practice Guidelines as Topic 9Platinum 9Early Intervention, Educational 9Cetuximab 9X-Rays 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lung Neoplasms × tislelizumab × 90 days × Clear all
NCT07019675 2026-05-08

A Study of SKB518 in Patients With Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
192 enrolled
Thoracic

Lung Neoplasms

NCT04699188 2026-03-18

KontRASt-01

Novartis

Phase 1/2 Active not recruiting
344 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07120282 2026-03-09

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
108 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡